Equities

Vytrus Biotech SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Vytrus Biotech SA

Actions
  • Price (EUR)12.60
  • Today's Change0.80 / 6.78%
  • Shares traded18.45k
  • 1 Year change--
  • Beta0.3057
Data delayed at least 15 minutes, as of Feb 16 2026 13:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vytrus Biotech SA, formerly Phyture Biotech SL, is Spain-based company principally engaged in the biotechnology industry. The Company develops high added value natural active ingredients on an industrial scale and provides ingredients and recombinant proteins for its use in the cosmetics and pharmaceutical sectors. The Company’s technology is based on using plant cell cultures to produce bioactive molecules. The Company obtains plant cells, known as Plant Stem Cell technology, which is applicable for cosmetics. Vytrus Biotech specifically target dermo-cosmetics as well as veterinary medicine, functional food and other pharmaceuticals, generating savings of more than 99% in natural resources.

  • Revenue in EUR (TTM)6.92m
  • Net income in EUR1.95m
  • Incorporated2009
  • Employees41.00
  • Location
    Vytrus Biotech SASant Gaieta 121, 2ndTERRASSA 08221SpainESP
  • Phone+34 931278106
  • Websitehttps://www.vytrus.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Carillion plc5.07bn-1.23bn65.03m31.63k------0.0128-2.49-2.499.74-1.011.1560.953.36139,493.50-27.663.40-60.046.407.939.31-24.103.490.71760.72031.7361.0011.241.14-6.48-1.6024.241.77
Exasol AG41.66m1.87m65.86m176.0035.2910.7717.771.580.06940.06941.550.22751.5842.1939.20236,693.307.09-45.087.27-47.1988.9493.914.48-54.4744.18--0.00--12.7612.89102.79---41.73--
Viafin Service Oyj99.61m4.76m70.58m685.0014.202.6110.710.70861.371.3728.687.461.986.956.58--9.698.9717.4116.9882.1781.374.894.841.1950.830.08752.128.7311.477.997.868.1916.47
Staffline Group Plc1.15bn19.32m71.05m2.32k4.061.853.250.06190.12430.03277.610.27284.98--8.56430,945.208.38-3.4040.29-10.676.588.031.68-0.8622--1.980.2953--13.96-1.36441.67---5.05--
Mcr SA125.41m7.99m72.04m811.009.021.395.560.57442.202.2034.2514.251.159.097.47--7.398.7811.2312.6722.7724.736.436.860.4276123.790.3729---5.965.08-67.26-5.62-5.41--
Star7 SpA118.46m2.95m77.40m1.41k26.232.506.290.65330.32790.327913.163.441.0721.053.3982,381.253.543.055.424.5658.6356.313.293.301.734.610.582--14.7718.5748.342.7226.72--
Spectra Systems Corp51.75m11.24m79.96m--7.002.265.701.550.20240.20240.93240.62830.97793.0210.96--21.2114.6527.3517.9250.0058.1421.6925.601.56--0.106878.40142.4630.0340.8814.4713.225.21
St Dupont SA56.37m756.00k86.25m240.00108.813.2019.251.530.00080.00080.06040.02860.9841.806.05234,866.701.32-7.922.11-14.4653.6252.791.34-8.960.9110.70430.2786--6.614.98262.72--4.62--
Vytrus Biotech SA6.92m1.95m90.09m41.0045.8910.0731.5413.020.25720.25720.91251.170.5812-0.76856.99187,042.2016.407.3018.558.27105.7683.5328.2116.722.7827.570.1375--35.0032.7987.36------
Veteranpoolen AB58.79m5.06m91.28m--20.6017.7017.711.552.642.6430.793.073.79-1.2011.38--32.5931.4391.7061.06100.10100.178.608.271.54--0.00112.4010.7811.116.439.30-13.05--
Amcomri Group PLC71.97m1.42m100.58m365.0070.643.9426.151.400.01720.01720.87120.30841.115.655.51171,460.302.14--3.35--36.58--1.94--1.021.910.4984--23.43--10.32------
Robert Walters PLC960.99m-17.02m103.19m3.13k--0.772810.810.1074-0.225-0.22512.701.602.38--5.26253,673.30-4.214.00-7.777.6035.3436.10-1.771.73---0.60870.445884.83-16.16-6.01-144.78--1.2339.18
AFYREN SA2.70m-11.36m103.63m130.00--1.62--38.35-0.435-0.4350.10351.770.0468--6.2520,784.62-19.69-10.66-20.87-11.5289.7194.07-420.28-204.98---1.170.0553---15.304.31-1.75---8.15--
Talenom Oyj129.62m6.22m103.96m1.52k16.601.813.540.8020.13670.13672.841.250.7143--6.9183,412.483.436.313.997.9397.5196.614.808.36--2.770.645595.293.7016.8581.20-4.3719.70-23.23
Catering International & Services SA459.92m7.27m112.57m16.44k15.491.685.380.24480.9040.90457.208.321.954.935.2428,826.013.822.759.976.2257.4257.901.961.621.073.990.361127.1829.649.7452.65-1.9215.27--
Data as of Feb 16 2026. Currency figures normalised to Vytrus Biotech SA's reporting currency: Euro EUR

Institutional shareholders

1.26%Per cent of shares held by top holders
HolderShares% Held
Andbank Wealth Management SGIIC SAUas of 31 Dec 202581.02k1.06%
Quadriga Asset Managers SGIIC SAas of 31 Dec 202512.81k0.17%
Renta 4 Gestora SGIIC SAas of 31 Dec 20252.00k0.03%
Data from 31 Dec 2025 - 11 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.